公开(公告)号：US20130165419A1

公开(公告)日：2013-06-27

申请号：US13333534

申请日：2011-12-21

Applicant: Richard L. Lindstrom ,  Kamran Hosseini ,  Lyle M. Bowman

Inventor： Richard L. Lindstrom ,  Kamran Hosseini ,  Lyle M. Bowman

IPC: A61K31/573 ,  A61P27/02 ,  A61P31/12 ,  A61P31/04 ,  A61P27/12 ,  A61P27/06 ,  A61P35/00 ,  A61P33/02 ,  A61P31/10 ,  A61P29/00 ,  A61P27/14

CPC classification number: A61K31/573 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/196 ,  A61K31/57 ,  A61K45/06 ,  A61K2300/00

Abstract: Compositions and systems for topical ophthalmic application, which include an aqueous mixture of steroidal and non-steroidal anti-inflammatory agents in a flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.

公开(公告)号：US20140142055A1

公开(公告)日：2014-05-22

申请号：US14233152

申请日：2012-06-29

Applicant: Kamran Hosseini ,  Lyle M. Bowman

Inventor： Kamran Hosseini ,  Lyle M. Bowman

IPC: A61K31/7052 ,  A61K31/573

CPC classification number: A61K31/7052 ,  A61K9/0048 ,  A61K31/573 ,  A61K31/7048 ,  A61K2300/00

Abstract: A method of treating a recurring meibomian gland disorder in a patient includes administering to a patient suffering from recurring meibomian gland disorder a composition comprising a therapeutically effective amount of an azalide antibiotic and a glucocorticoid. The method may thereby reduce the frequency of recurrence of the meibomian gland disorder.

Abstract translation: 一种治疗患者中复发性睑板腺疾病的方法包括向患有复发性睑板腺疾病的患者施用包含治疗有效量的氮杂大环内酯抗生素和糖皮质激素的组合物。 该方法可能因此降低睑板腺疾病复发的频率。

公开(公告)号：US20130177599A1

公开(公告)日：2013-07-11

申请号：US13345087

申请日：2012-01-06

Applicant: Lyle M. BOWMAN ,  Kamran Hosseini

Inventor： Lyle M. BOWMAN ,  Kamran Hosseini

IPC: A61K31/78 ,  A61P27/02 ,  A61K9/14

CPC classification number: C11D3/3765 ,  A61K9/0048 ,  C11D3/0078

Abstract: Provided are method and kits useful for extending the wear-time of a contact lens. The method includes applying an amount of an ophthalmically acceptable solution to the contact lens to improve the comfort of the eye when the contact lens is in the eye. The solution includes an aqueous suspension and chitosan. The aqueous suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. Upon contact with tear fluid, the solution gels to a second viscosity which is greater than the first viscosity. The kit includes contact lenses, an ophthalmically acceptable solution and instructions for applying the solution to improve the comfort of the eye when the contact lens is in the eye.

Abstract translation: 提供了用于延长隐形眼镜的磨损时间的方法和试剂盒。 该方法包括将一定量的眼科可接受的溶液施加到隐形眼镜，以在隐形眼镜在眼睛中时提高眼睛的舒适度。 该溶液包括水性悬浮液和壳聚糖。 含水悬浮液包含约0.1重量％至约6.5重量％的通过聚合一种或多种含羧基的单烯属不饱和单体和小于约5重量％的交联剂制备的含羧基聚合物。 当与泪液接触时，溶液凝胶化至大于第一粘度的第二粘度。 该套件包括隐形眼镜，眼科可接受的解决方案以及当隐形眼镜在眼睛中时施加该溶液以改善眼睛的舒适性的说明书。

公开(公告)号：US07678078B1

公开(公告)日：2010-03-16

申请号：US12288510

申请日：2008-10-21

Applicant: Gholam A. Peyman ,  Michel Jean Noel Cormier ,  Kamran Hosseini

Inventor： Gholam A. Peyman ,  Michel Jean Noel Cormier ,  Kamran Hosseini

IPC: A61M5/00

CPC classification number: A61F9/0017 ,  A61M5/24 ,  A61M5/46 ,  A61M2005/2407 ,  A61M2005/2488 ,  A61M2005/31516

Abstract: An intravitreal injection device for administering a pharmacological agent formulation to an intravitreal compartment of an eye, comprising (i) a nozzle member having an internal formulation chamber that is adapted to receive and contain the pharmacological agent formulation therein, (ii) a microneedle having a first end that is in communication with the nozzle member and a second ejection end, (iii) and piercing depth limiter means for limiting the penetration depth of the microneedle into the eye, the microneedle piercing depth limiter means including guide means for positioning the limiter means and guiding the microneedle.

Abstract translation: 一种玻璃体内注射装置，其用于向眼睛的玻璃体腔内施用药物制剂，其包括（i）具有内部制剂室的喷嘴构件，所述内部配制腔适于接纳并容纳其中的药物制剂;（ii）微针，其具有 与喷嘴构件连通的第一端和第二排出端，（iii）和刺穿深度限制器装置，用于将微针的穿透深度限制到眼睛中，微针刺穿深度限制装置包括用于定位限制装置的引导装置 并引导微针。

公开(公告)号：US10201548B2

公开(公告)日：2019-02-12

申请号：US12399729

申请日：2009-03-06

Applicant: Lyle Bowman ,  Kamran Hosseini

Inventor： Lyle Bowman ,  Kamran Hosseini

IPC: A61K31/56

Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.

公开(公告)号：US20130023575A1

公开(公告)日：2013-01-24

申请号：US13188730

申请日：2011-07-22

Applicant: Kamran Hosseini ,  Lyle Bowman

Inventor： Kamran Hosseini ,  Lyle Bowman

IPC: A61K31/196 ,  A61P27/14 ,  A61P9/08 ,  A61K31/4174

CPC classification number: A61K31/196 ,  A61K9/0046 ,  A61K31/137 ,  A61K31/4164 ,  A61K31/4174 ,  A61K45/06 ,  A61K2300/00

Abstract: The disclosure provides ophthalmic compositions, systems and methods for the treatment of ocular surface allergies. More particularly the present invention relates to compositions of bromfenac for the treatment of the signs and symptoms of ocular surface allergies due to seasonal allergies.

Abstract translation: 本公开提供了用于治疗眼表过敏症的眼用组合物，系统和方法。 更具体地，本发明涉及溴芬酸的组合物，用于治疗由于季节性过敏引起的眼表过敏的体征和症状。

公开(公告)号：US08430862B2

公开(公告)日：2013-04-30

申请号：US12932941

申请日：2011-03-09

Applicant: Gholam A. Peyman ,  Michel Jean Noel Cormier ,  Kamran Hosseini

Inventor： Gholam A. Peyman ,  Michel Jean Noel Cormier ,  Kamran Hosseini

IPC: A61H33/04 ,  A61M31/00

CPC classification number: A61F9/0017 ,  A61M37/0015

Abstract: A subconjunctival injection apparatus for administering a pharmacological agent formulation to a subconjunctival compartment of an eye, the apparatus including a jet injector having force generating means that is adapted to generate sufficient force to expel the pharmacological agent formulation from the jet injector and through the conjunctiva. In one embodiment of the invention, the jet injector comprises a needleless jet injector. In one embodiment, the needleless jet injector provides a delivery pressure in the range of approximately 100-1000 psi.

Abstract translation: 一种用于向眼结膜下室施用药物制剂的结膜下注射装置，所述装置包括具有力产生装置的喷射注射器，所述力产生装置适于产生足够的力以从药剂制剂从喷射器排出并通过结膜。 在本发明的一个实施例中，射流喷射器包括无针喷射喷射器。 在一个实施例中，无针喷射喷射器提供在约100-1000psi范围内的输送压力。

公开(公告)号：US20110251586A1

公开(公告)日：2011-10-13

申请号：US12932941

申请日：2011-03-09

Applicant: Gholam A. Peyman ,  Michael Jean Noel Cormier ,  Kamran Hosseini

Inventor： Gholam A. Peyman ,  Michael Jean Noel Cormier ,  Kamran Hosseini

IPC: A61F9/00

CPC classification number: A61F9/0017 ,  A61M37/0015

Abstract: A subconjunctival injection apparatus for administering a pharmacological agent formulation to a subconjunctival compartment of an eye, the apparatus including a jet injector having force generating means that is adapted to generate sufficient force to expel the pharmacological agent formulation from the jet injector and through the conjunctiva. In one embodiment of the invention, the jet injector comprises a needleless jet injector. In one embodiment, the needleless jet injector provides a delivery pressure in the range of approximately 100-1000 psi.

Abstract translation: 一种用于向眼结膜下室施用药物制剂的结膜下注射装置，所述装置包括具有力产生装置的喷射注射器，所述力产生装置适于产生足够的力以从药剂制剂从喷射器排出并通过结膜。 在本发明的一个实施例中，射流喷射器包括无针喷射喷射器。 在一个实施例中，无针喷射喷射器提供在约100-1000psi范围内的输送压力。

公开(公告)号：US20100100054A1

公开(公告)日：2010-04-22

申请号：US12456439

申请日：2009-06-16

Applicant: Michel Cormier ,  Gholam Peyman ,  Kamran Hosseini

Inventor： Michel Cormier ,  Gholam Peyman ,  Kamran Hosseini

IPC: A61M5/32

CPC classification number: A61F9/0017 ,  A61M5/24 ,  A61M5/46 ,  A61M2005/2407 ,  A61M2005/2488

Abstract: An intravitreal injection system for administering a pharmacological agent formulation to an intravitreal compartment of an eye, comprising (i) an injection member coupled to, or comprising, an internal formulation chamber that is adapted to receive and contain the pharmacological agent formulation therein, (ii) a needle having a first end that is in communication with a formulation chamber and a second injection end, and (iii) a movable platform for positioning the system on the eye, guiding the needle, and limiting the penetration depth of the needle into the eye.

Abstract translation: 一种玻璃体内注射系统，用于向眼睛的玻璃体腔内施用药物制剂，其包含（i）与适于在其中接受和容纳其药理学制剂的内部制剂室耦合或包含的注射构件（ii） ）具有与制剂室和第二注射端连通的第一端的针，以及（iii）用于将系统定位在眼睛上的引导针，并且将针的穿入深度限制到 眼。

公开(公告)号：US08221353B2

公开(公告)日：2012-07-17

申请号：US12456439

申请日：2009-06-16

Applicant: Michel Cormier ,  Gholam Peyman ,  Kamran Hosseini

Inventor： Michel Cormier ,  Gholam Peyman ,  Kamran Hosseini

IPC: A61M5/00

CPC classification number: A61F9/0017 ,  A61M5/24 ,  A61M5/46 ,  A61M2005/2407 ,  A61M2005/2488

Abstract: An intravitreal injection system for administering a pharmacological agent formulation to an intravitreal compartment of an eye, comprising (i) an injection member coupled to, or comprising, an internal formulation chamber that is adapted to receive and contain the pharmacological agent formulation therein, (ii) a needle having a first end that is in communication with a formulation chamber and a second injection end, and (iii) a movable platform for positioning the system on the eye, guiding the needle, and limiting the penetration depth of the needle into the eye.

Abstract translation: 一种玻璃体内注射系统，用于向眼睛的玻璃体腔内施用药物制剂，其包含（i）与适于在其中接受和容纳其药理学制剂的内部制剂室耦合或包含的注射构件（ii） ）具有与制剂室和第二注射端连通的第一端的针，以及（iii）用于将系统定位在眼睛上的引导针，并且将针的穿入深度限制到 眼。